Understanding the tumor microenvironment for effective immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Understanding the tumor immune microenvironment (TIME) for effective therapy

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145

New functions for the matrix metalloproteinases in cancer progression

Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 4×

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352

Reactive oxygen species (ROS) as pleiotropic physiological signalling agents

Sies, H., & Jones, D. P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0230-3 · Cited by 5,335

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

Fibroblasts in cancer

Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538

The biology and function of fibroblasts in cancer

Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520

Fundamentals of Cancer Metabolism

DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733

Dendritic cells in cancer immunology and immunotherapy

Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,688

NF-κB, inflammation, immunity and cancer: coming of age

Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679

Hallmarks of Cellular Senescence

Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,559

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,248

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157

Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress

Sies, H. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.035 · Cited by 2,148

T Cell Activation

Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141

The extracellular matrix modulates the hallmarks of cancer

Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO Reports · doi:10.15252/embr.201439246 · Cited by 2,098

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053

Turning foes to friends: targeting cancer-associated fibroblasts

Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,929

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635

Immune evasion in cancer: mechanistic basis and therapeutic strategies

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 1×

CD4+ T cell help in cancer immunology and immunotherapy

Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585

Immune-related adverse events of checkpoint inhibitors

Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491

CD8+ T cell states in human cancer: insights from single-cell analysis

van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,487

Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy

Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · cited 2×

CCR7 and its ligands: balancing immunity and tolerance

Förster, R., Davalos-Misslitz, A. C., & Rot, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2297 · Cited by 1,410

Emerging landscape of oncogenic signatures across human cancers

Ciriello, G., Miller, M. L., Aksoy, B. A., Şenbabaoğlu, Y., Schultz, N. D., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,401

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C. B., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,389

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 1×

Perforin and granzymes: function, dysfunction and human pathology

Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,287

Cellular Adaptation to Hypoxia through Hypoxia Inducible Factors and beyond

Lee, P., Chandel, N. S., & Simon, M. C. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0227-y · Cited by 1,272

Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

Salmon, H., Idoyaga, J., Rahman, A. H., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M. N., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,222

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191

Natural Killer Cells: Development, Maturation, and Clinical Utilization

Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142

Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma

Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101

Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer

Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095

Targeting natural killer cells in cancer immunotherapy

Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,081

Natural killer cells and other innate lymphoid cells in cancer

Chiossone, L., Dumas, P., Vienne, M., & Vivier, É. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,034

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000

Neutrophils support lung colonization of metastasis-initiating breast cancer cells

Wculek, S. K., & Malanchi, I. (2015) · Nature · doi:10.1038/nature16140 · Cited by 996

The epigenetic landscape of T cell exhaustion

Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986

Effector and Memory CTL Differentiation

Williams, M. A., & Bevan, M. J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141548 · Cited by 980

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 953

Targeting tumor-associated macrophages in cancer

Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933

Memory CD8 T-Cell Differentiation during Viral Infection

Wherry, E. J., & Ahmed, R. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5535-5545.2004 · Cited by 889

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 871

Tumor-associated macrophages: from basic research to clinical application

Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction

Castellino, F., Huang, A. Y.-C., Altan-Bonnet, G. Y., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 847

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

Tay, R. E., Richardson, E. K., & Toh, H. C. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 844

The role of cellular reactive oxygen species in cancer chemotherapy

Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M., & Liang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0909-x · Cited by 794

The future of cancer immunotherapy: microenvironment-targeting combinations

Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 768

T-helper-1-cell cytokines drive cancer into senescence

Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706

Mast cells as sources of cytokines, chemokines, and growth factors

Mukai, K., Tsai, M. M., Saito, H., & Galli, S. J. (2018) · Immunological Reviews · doi:10.1111/imr.12634 · Cited by 704

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Gao, Y., Souza-Fonseca-Guimarães, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 681

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 679

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

Viel, S., Marçais, A., Souza-Fonseca-Guimarães, F., Loftus, R. M., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 675

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J. L., Ruhland, M. K., Kersten, K., Abushawish, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 654

Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors

Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653

Biology and regulation of IL-2: from molecular mechanisms to human therapy

Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637

Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Nguyen, L. T., & Ohashi, P. S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3790 · Cited by 634

Why are tumour blood vessels abnormal and why is it important to know?

Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611

Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells

Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

Ugel, S., Sanctis, F. D., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 574

The Extracellular Matrix Modulates the Metastatic Journey

Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 561

Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

Mandal, R., Samstein, R. M., Lee, K.-W., Havel, J. J., Wang, H., Krishna, C., Sabio, E. Y., Makarov, V., Kuo, F., Blecua, P., et al. (2019) · Science · doi:10.1126/science.aau0447 · Cited by 554

In Vivo CD4 + T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm

Ruterbusch, M., Pruner, K. B., Shehata, L., & Pepper, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-103019-085803 · Cited by 550

RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues

Yizhak, K., Aguet, F., Kim, J., Hess, J. M., Kübler, K., Grimsby, J., Frazer, R., Zhang, H., Haradhvala, N. J., Rosebrock, D., et al. (2019) · Science · doi:10.1126/science.aaw0726 · Cited by 500

T-bet: a bridge between innate and adaptive immunity

Lazarevic, V., Glimcher, L. H., & Lord, G. M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3536 · Cited by 486 · cited 1×

The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective

Galon, J., Fridman, W. H., & Pagès, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4806 · Cited by 464

Therapeutic targeting of trained immunity

Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0025-4 · Cited by 456

Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma

Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3556 · Cited by 455

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455

Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13)

Kirshenbaum, A. S., Goff, J. P., Semere, T., Foster, B. A., Scott, L. M., & Metcalfe, D. D. (1999) · Blood · doi:10.1182/blood.v94.7.2333.419k30_2333_2342 · Cited by 420

CAR-T cells: the long and winding road to solid tumors

D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L., & Alimandi, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0278-6 · Cited by 412

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

Klempner, S. J., Fabrizio, D. A., Bane, S., Reinhart, M. L., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G. M., Schrock, A. B., Anhorn, R., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0244 · Cited by 411

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment

Young, A., Ngiow, S. F., Gao, Y., Patch, A., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 406

The Immunoscore: Colon Cancer and Beyond

Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., & Galon, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1851 · Cited by 399

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7431 · Cited by 394

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 389

Driver and Passenger Mutations in Cancer

Pon, J. R., & Marra, M. A. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 381

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

Cohen, C. J., Gartner, J. J., Horovitz‐Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., Parkhurst, M. R., Ankri, C., Prickett, T. D., Crystal, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82416 · Cited by 380

Expression profiling of constitutive mast cells reveals a unique identity within the immune system

Dwyer, D. F., Barrett, N. A., & Austen, K. F. (2016) · Nature Immunology · doi:10.1038/ni.3445 · Cited by 373

Immunoregulation by members of the TGFβ superfamily

Chen, W., & ten Dijke, P. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.112 · Cited by 360

Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers

Pearce, O. M. T., Delaine‐Smith, R. M., Maniati, E., Nichols, S., Wang, J., Böhm, S., Rajeeve, V., Ullah, D., Chakravarty, P., Jones, R. R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0284 · Cited by 348

Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms

Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 340

Transcriptional regulation of granulocyte and monocyte development

Friedman, A. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205324 · Cited by 333

Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement

Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 328

Neutrophils: key mediators of tumour angiogenesis

Tazzyman, S. J., Lewis, C. E., & Murdoch, C. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00641.x · Cited by 326

Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma

Czystowska, M., Sosnowska, A., Nowis, D., Ramji, K., Szajnik, M. E., Chlebowska, J., Wolińska, E., Gaj, P., Grażul, M., Pilch, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10979-3 · Cited by 325

Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence

Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 323

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322

ROS homeostasis and metabolism: a critical liaison for cancer therapy

Kim, J., Kim, J., & Bae, J. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.119 · Cited by 304

Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non–Small-Cell Lung Cancer

Swinson, D., Jones, J. L., Richardson, D. L., Wykoff, C. C., Turley, H., Pastorek, J., Taub, N. A., Harris, A. L., & O'Byrne, K. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.132 · Cited by 288

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

Ock, C.-Y., Keam, B., Kim, S., Lee, J., Kim, M., Kim, T. M., Jeon, Y. K., Kim, D., Chung, D. H., & Heo, D. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2834 · Cited by 269

Neutrophil-derived chemokines on the road to immunity

Tecchio, C., & Cassatella, M. A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.04.003 · Cited by 261

Hallmarks of response to immune checkpoint blockade

Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 251

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248

Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer

Singhal, S. K., Stadanlick, J. E., Annunziata, M. J., Rao, A. S., Bhojnagarwala, P. S., O’Brien, S., Moon, E. K., Cantu, E., Danet-Desnoyers, G. A., Ra, H.-J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat1500 · Cited by 248

CRISPR screen in regulatory T cells reveals modulators of Foxp3

Cortez, J. T., Montauti, E. I., Shifrut, E., Gatchalian, J., Zhang, Y., Shaked, O., Xu, Y., Roth, T. L., Simeonov, D. R., Zhang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2246-4 · Cited by 246

Migratory CD11b + conventional dendritic cells induce T follicular helper cell–dependent antibody responses

Krishnaswamy, J. K., Gowthaman, U., Zhang, B., Mattsson, J., Szeponik, L., Liu, D., Wu, R., White, T. L., Calabrό, S., Xu, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aam9169 · Cited by 245

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts

Fumet, J.-D., Truntzer, C., Yarchoan, M. M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 242

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Håkansson, L., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 235

Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis

Marshall, E. A., Ng, K. W., Kung, S. H. Y., Conway, E. M., Martínez, V. D., Halvorsen, E. C., Rowbotham, D. A., Vucic, E. A., Plumb, A. W., Becker‐Santos, D. D., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0551-1 · Cited by 233

Tcf1 and Lef1 transcription factors establish CD8+ T cell identity through intrinsic HDAC activity

Xing, S., Li, F., Zeng, Z., Zhao, Y., Yu, S., Shan, Q., Li, Y., Phillips, F. C., Maina, P. K., Qi, H. H., et al. (2016) · Nature Immunology · doi:10.1038/ni.3456 · Cited by 226

IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis

Bishnupuri, K. S., Alvarado, D. M., Khouri, A. N., Shabsovich, M., Chen, B., Dieckgraefe, B. K., & Ciorba, M. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0668 · Cited by 215

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

Thompson, J. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0047 · Cited by 209

Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression

Kondo, A., Yamamoto, S., Nakaki, R., Shimamura, T., Hamakubo, T., Sakai, J., Kodama, T., Yoshida, T., Aburatani, H., & Osawa, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.006 · Cited by 205

Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation

Plum, T., Wang, X., Rettel, M., Krijgsveld, J., Feyerabend, T. B., & Rodewald, H.-R. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.012 · Cited by 200

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

Xiao, G., Jin, L.-L., Liu, C., Wang, Y., Meng, Y.-M., Zhou, Z., Chen, J., Yu, X.-J., Zhang, Y., Xu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0784-9 · Cited by 186

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

Fultang, L., Panetti, S., Ng, M. H. L., Collins, P. J., Graef, S., Rizkalla, N., Booth, S., Lenton, R., Noyvert, B., Shannon-Lowe, C. D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.025 · Cited by 170

Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway

Lv, Y.-P., Zhao, Y., Wang, X., Chen, N., Mao, F., Teng, Y., Wang, T., Peng, L., Zhang, J., Cheng, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0530-3 · Cited by 165

The Role of the Tumor Microenvironment in Regulating AngiogenesisPreprint

Watnick, R. S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006676 · Cited by 162

Treg(s) in Cancer: Friends or Foe?

Wolf, D. G. F., Sopper, S., Pircher, A., Gastl, G. A., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 157

The opposing roles of CD 4+ T cells in anti‐tumour immunity

Ahrends, T., & Borst, J. G. (2018) · Immunology · doi:10.1111/imm.12941 · Cited by 144

Maximal T Cell–Mediated Antitumor Responses Rely upon CCR5 Expression in Both CD4+ and CD8+ T Cells

González-Martín, A., Gómez, L., Lustgarten, J., Mira, E., & Mañes, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1687 · Cited by 141

Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy

Morein, D., Erlichman, N., & Ben‐Baruch, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00952 · Cited by 138

Cellular and molecular mechanisms in cancer immune escape: a comprehensive review

Bhatia, A., & Kumar, Y. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865519 · Cited by 136

Chemotherapy and immunotherapy: mapping the road ahead

Cook, A., Lesterhuis, W. J., Nowak, A. K., & Lake, R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.003 · Cited by 134

The Damaging Effect of Passenger Mutations on Cancer Progression

McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3283-t · Cited by 126

Recruitment of CD103 + dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy

Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 125

Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1–5 and Superoxide Dismutase 1–3 Signal Transduction Pathways

Parascandolo, A., & Laukkanen, M. O. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7268 · Cited by 119

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

Zugazagoitia, J., Gupta, S., Liu, Y., Fuhrman, K. A., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0175 · Cited by 116

Tcf7 Is an Important Regulator of the Switch of Self-Renewal and Differentiation in a Multipotential Hematopoietic Cell Line

Wu, J. Q., Seay, M., Schulz, V., Hariharan, M., Tuck, D. P., Lian, J., Du, J., Shi, M., Ye, Z., Gerstein, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002565 · Cited by 108

Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function

Konopacki, C., Pritykin, Y., Rubtsov, Y. P., Leslie, C. S., & Rudensky, A. Y. (2019) · Nature Immunology · doi:10.1038/s41590-018-0291-z · Cited by 104

High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors

Marçais, A., Marotel, M., Degouve, S., Koenig, A., Fauteux‐Daniel, S., Drouillard, A., Schlums, H., Viel, S., Besson, L., Allatif, O., et al. (2017) · eLife · doi:10.7554/elife.26423 · Cited by 101

Conformational coupling of integrin and Thy-1 regulates Fyn priming and fibroblast mechanotransduction

Fiore, V. F., Strane, P. W., Bryksin, A. V., White, E. S., Hagood, J. S., & Barker, T. H. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201505007 · Cited by 93

Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis

Yoon, H. H., Shi, Q., Heying, E. N., Murányi, A., Bredno, J., Ough, F., Djalilvand, A., Clements, J., Bowermaster, R., Liu, W.-W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1984 · Cited by 89

Tumour islet Foxp3+T-cell infiltration predicts poor outcome in nonsmall cell lung cancer

O’Callaghan, D. S., Rexhepaj, E., Gately, K. A., Coate, L. E., Delaney, D., O’Donnell, D. M., Kay, E. W., O’Connell, F., Gallagher, W. M., & O'Byrne, K. J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00176-2014 · Cited by 87

Harnessing Natural Killer Immunity in Metastatic SCLC

Best, S. A., Hess, J. B., Souza-Fonseca-Guimarães, F., Cursons, J., Kersbergen, A. J., Dong, X., Rautela, J., Hyslop, S. R., Ritchie, M. E., Davis, M. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.008 · Cited by 84

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer

Barr, M. P., Gray, S. G., Gately, K. A., Hams, E., Fallon, P. G., Davies, A. M., Richard, D. J., Pidgeon, G. P., & O'Byrne, K. J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0310-8 · Cited by 81

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity

Rautela, J., Dagley, L. F., de Oliveira, C. C., Schuster, I. S., Hediyeh-zadeh, S., Delconte, R. B., Cursons, J., Hennessy, R. J., Hutchinson, D. S., Harrison, C. A., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat7527 · Cited by 79

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma

Wong, P. F., Wei, W., Gupta, S., Smithy, J. W., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0675-0 · Cited by 77

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells

Gallego‐Ortega, D., Ledger, A., Roden, D. L., Law, A. M. K., Magenau, A., Kikhtyak, Z., Cho, C., Allerdice, S. L., Lee, H. J., Valdés‐Mora, F., et al. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002330 · Cited by 73

Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment

Danelli, L., Frossi, B., Gri, G., Mion, F., Guarnotta, C., Bongiovanni, L., Tripodo, C., Mariuzzi, L., Marzinotto, S., Rigoni, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0102 · Cited by 72

Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma

Zhao, J., Hou, Y., Yin, C., Hu, J. R., Gao, T., Huang, X., Zhang, X., Xing, J., An, J., Wan, S., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1093-y · Cited by 60

Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?

Liebl, M. C., & Hofmann, T. G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15992 · Cited by 58

Induction of DNMT3B by PGE2 and IL6 at Distant Metastatic Sites Promotes Epigenetic Modification and Breast Cancer Colonization

So, J. Y., Skrypek, N., Yang, H. H., Merchant, A. S., Nelson, G. W., Chen, W.-D. D., Ishii, H., Chen, J. M., Hu, G., Achyut, B. R., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3339 · Cited by 53

Molecular classification and precision therapy of cancer: immune checkpoint inhibitors

Yu, Y. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0581-0 · Cited by 51

Tumor Immuno-Environment in Cancer Progression and Therapy

Kaliński, P., & Talmadge, J. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_1 · Cited by 49

Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy

Cha, Y. J., Park, E. J., Baik, S. H., Lee, K. Y., & Kang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-48140-1 · Cited by 40

The dual role of mast cells in tumor fate

Ribatti, D., Tamma, R., & Crivellato, E. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.005 · Cited by 39

Regulation of CTL Infiltration Within the Tumor Microenvironment

Church, S., & Galon, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_3 · Cited by 36

Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma

Liu, S., Bian, L., Liu, Z., Chen, Q., Sun, X.-S., Sun, R., Luo, D., Li, X. N., Xiao, B.-B., Yan, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000205 · Cited by 35

Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung

Tashima, Y., Kuwata, T., Yoneda, K., Hirai, A., Mori, M., Kanayama, M., Imanishi, N., Kuroda, K., Ichiki, Y., & Tanaka, F. (2020) · Scientific Reports · doi:10.1038/s41598-019-57321-x · Cited by 34

Take lessons from cancer evolution to the clinic

Swanton, C. (2020) · Nature · doi:10.1038/d41586-020-01347-z · Cited by 26

ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells

Mohammed, R. N., Wehenkel, S. C., Galkina, E., Yates, E.-K., Preece, G., Newman, A., Watson, H. A., Ohme, J., Bridgeman, J. S., Durairaj, R. R. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41811-z · Cited by 21

Fas/FasL signaling is critical for the survival of exhausted antigen-specific CD8+ T cells during tumor immune response

Yajima, T., Hoshino, K., Muranushi, R., Mogi, A., Onozato, R., Yamaki, E., Kosaka, T., Tanaka, S., Shirabe, K., Yoshikai, Y., et al. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.01.014 · Cited by 21

Drug development: Releasing the brakes

Weintraub, K. (2013) · Nature · doi:10.1038/504s6a · Cited by 19

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353

Defect Engineering in Nanocatalysts: From Design and Synthesis to Applications

Muhammad, P., Zada, A., Rashid, J., Hanif, S., Gao, Y., Li, C., Li, Y., Fan, K., & Wang, Y. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314686 · Cited by 374

Targeting the Warburg Effect in Cancer: Where Do We Stand?

Barba, I., Carrillo-Bosch, L., & Seoane, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063142 · Cited by 276

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalçın, Ş. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 220

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213

The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies

Sadeghirad, H., Bazaz, S. R., Monkman, J. H., Warkiani, M. E., Rezaei, N., O'Byrne, K. J., & Kulasinghe, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1215 · Cited by 37

Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment

Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 13

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169

Role of tumor microenvironment in regulator of tumor progression and immunotherapy

周平平 (2026) · Discover Oncology · doi:10.1007/s12672-026-04421-6 · Cited by 4

Research Progress on the Regulation of Tumor Microenvironment in Immunotherapy

Ren, J., Xie, W., & Zhang, H. (2025) · Journal of Contemporary Medical Practice · doi:10.53469/jcmp.2025.07(04).51